Calandri M, Brino J, Yevich S, Pujol J, Zarqane H, Bonnet B
Eur Radiol. 2025; .
PMID: 40055230
DOI: 10.1007/s00330-025-11466-8.
Zhu W, Zhang Y, Yang L, Chen L, Chen C, Shi Q
Oncol Lett. 2025; 29(3):155.
PMID: 39911153
PMC: 11795234.
DOI: 10.3892/ol.2025.14902.
Lv R, Chen J, Wu X, Chai K, Yan J, Wang S
Discov Oncol. 2025; 16(1):42.
PMID: 39806139
PMC: 11729587.
DOI: 10.1007/s12672-025-01778-y.
Wu Y, Miao K, Chen M, Xu Y, Zhong W, Wang H
Thorac Cancer. 2024; 15(35):2474-2485.
PMID: 39468864
PMC: 11646693.
DOI: 10.1111/1759-7714.15470.
Wang L, Chen H, Deng L, Hu M, Wang Z, Zhang K
Front Oncol. 2024; 14:1449143.
PMID: 39450260
PMC: 11499198.
DOI: 10.3389/fonc.2024.1449143.
Preliminary exploration of poor prognostic factor IL-33 and its involvement in perioperative immunotherapy in stage II-III lung squamous cell carcinoma: a retrospective cohort study.
Liu Y, Liu P, Zhang R, Seki N, Forest F, Brueckl W
J Thorac Dis. 2024; 16(9):6204-6215.
PMID: 39444909
PMC: 11494545.
DOI: 10.21037/jtd-24-1122.
Establish a novel immune-related gene prognostic risk index (IRGPRI) associated with CD8+ cytotoxic T lymphocytes in non-small-cell lung cancer (NSCLC).
Cui S, Yang Y, Lou S, Huang R, Wang J, Chen Z
Heliyon. 2024; 10(19):e38324.
PMID: 39397989
PMC: 11466668.
DOI: 10.1016/j.heliyon.2024.e38324.
Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.
Nguyen C, Van T, Huong P
Cancer Control. 2024; 31:10732748241285474.
PMID: 39285591
PMC: 11406641.
DOI: 10.1177/10732748241285474.
Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer.
Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R
Cancer Med. 2024; 13(16):e70083.
PMID: 39206619
PMC: 11358701.
DOI: 10.1002/cam4.70083.
Editorial: Advances in novel pharmacotherapeutics and drug discovery: computational, experimental, translational, and clinical models.
Sandoval C, Torrens F, Souza-Mello V, Farias J
Front Pharmacol. 2024; 15:1465835.
PMID: 39185305
PMC: 11341978.
DOI: 10.3389/fphar.2024.1465835.
Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation.
Shi Y, Xu Y, Wang M
BMC Cancer. 2024; 24(1):1043.
PMID: 39179992
PMC: 11342509.
DOI: 10.1186/s12885-024-12797-3.
Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management.
Dhingra S, Goyal S, Thirumal D, Sharma P, Kaur G, Mittal N
Nanomedicine (Lond). 2024; 19(15):1331-1346.
PMID: 39105754
PMC: 11318747.
DOI: 10.1080/17435889.2024.2348438.
Deciphering the prognostic role of endoplasmic reticulum stress in lung adenocarcinoma: integrating prognostic prediction and immunotherapy strategies.
Wen B, Zhang P, Xie J, Zhou Z, Zhang G, Zhang L
Clin Exp Med. 2024; 24(1):169.
PMID: 39052154
PMC: 11272744.
DOI: 10.1007/s10238-024-01439-4.
Therapeutic and prognostic effect of disulfidptosis-related genes in lung adenocarcinoma.
Li C, Sun C, Li Y, Dong L, Wang X, Li R
Heliyon. 2024; 10(13):e33764.
PMID: 39050421
PMC: 11267016.
DOI: 10.1016/j.heliyon.2024.e33764.
Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country.
Osorio A, Fernandez-Trujillo L, Restrepo J, Sua L, Proano C, Zuniga-Restrepo V
Cancer Manag Res. 2024; 16:781-789.
PMID: 39010861
PMC: 11249106.
DOI: 10.2147/CMAR.S455809.
The Association between Dyslipidemia and Pulmonary Diseases.
Isago H
J Atheroscler Thromb. 2024; 31(9):1249-1259.
PMID: 39010219
PMC: 11374539.
DOI: 10.5551/jat.RV22021.
Temporin-GHaK Exhibits Antineoplastic Activity against Human Lung Adenocarcinoma by Inhibiting the Wnt Signaling Pathway through miRNA-4516.
Liu Y, Liu H, Zhang J, Zhang Y
Molecules. 2024; 29(12).
PMID: 38930863
PMC: 11206823.
DOI: 10.3390/molecules29122797.
Investigation of Lung Cancer Cell Response to Cryoablation and Adjunctive Gemcitabine-Based Cryo-Chemotherapy Using the A549 Cell Line.
Santucci K, Snyder K, Van Buskirk R, Baust J, Baust J
Biomedicines. 2024; 12(6).
PMID: 38927445
PMC: 11200978.
DOI: 10.3390/biomedicines12061239.
Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome.
Li S, Li W, Liu B, Krysan K, Dubinett S
Cancer Res Commun. 2024; 4(7):1738-1747.
PMID: 38856716
PMC: 11249519.
DOI: 10.1158/2767-9764.CRC-23-0564.
Characteristics of mast cell infiltration in lung adenocarcinoma and its impact on prognosis.
Qiu Z, Pang G, Xu X, Lin J, Wang P
Discov Oncol. 2024; 15(1):208.
PMID: 38834833
PMC: 11150364.
DOI: 10.1007/s12672-024-01062-5.
